Lenvima and Constipation - a phase IV clinical study of FDA data

Summary:

Constipation is reported as a side effect among people who take Lenvima (lenvatinib mesylate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Keytruda, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Constipation when taking Lenvima. It is created by eHealthMe based on reports of 21,107 people who have side effects when taking Lenvima from the FDA, and is updated regularly.

What is Lenvima?

Lenvima has active ingredients of lenvatinib mesylate. eHealthMe is studying from 21,113 Lenvima users. Check the latest studies of Lenvima.

What is Constipation?

Constipation is found to be associated with 3,004 drugs and 4,602 conditions by eHealthMe. Check the latest studies of Constipation.

On Feb, 19, 2026

21,107 people reported to have side effects when taking Lenvima.
Among them, 729 people (3.45%) have Constipation.

Among these 729 people:

* Approximation only. Some reports may have incomplete information.

Do you take Lenvima and have Constipation?

- Check whether Constipation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lenvima:

Lenvima (21,113 reports)

Constipation treatments and more:

Constipation (337,876 reports)

How severe was Constipation and when was it recovered:

Constipation in Lenvima

Expand to all the drugs that have ingredients of lenvatinib mesylate:

Constipation and drugs with ingredients of lenvatinib mesylate (1,003 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lenvima:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Constipation:

Constipation (3,004 drugs)

Browse all the conditions that are associated with Constipation:

Constipation (4,602 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lenvatinib mesylate (the active ingredients of Lenvima) and Lenvima (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.